Genomic Classification and Prognosis in Acute Myeloid LeukemiaElli Papaemmanuil, Peter J. Campbell, Moritz Gerstung et al.|New England Journal of Medicine|2016Cited by 4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L. Levine, D. Gary Gilliland, Sandra Moore et al.|Cancer Cell|2005Cited by 3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> MutationRichard M. Stone, Hartmut Döhner, Sumithra J. Mandrekar et al.|New England Journal of Medicine|2017Cited by 2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaFrancesco Lo‐Coco, Uwe Platzbecker, Giuseppe Avvisati et al.|New England Journal of Medicine|2013Cited by 1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Michael Heuser et al.|Blood|2018Cited by 1k